Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
In this review, we will examine key preclinical studies that demonstrated the mechanistic role of IL-17A in the development SpA and discuss how these observations were translated into clinical practice.
|
28270233 |
2017 |
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Clinical improvement in joint counts was associated with a histologic decrease in synovial sublining macrophages (P = 0.028) and neutrophils (P = 0.004), both of which are sensitive synovial biomarkers of inflammatory response in peripheral SpA, as well as with decreased synovial expression of IL-17A messenger RNA (mRNA) (P = 0.010) but not of tumor necrosis factor mRNA.
|
29869838 |
2018 |
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Spondyloarthritis encompasses a group of common inflammatory diseases thought to be driven by IL-17A-secreting type-17 lymphocytes.
|
29142230 |
2017 |
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
RGD |
Proinflammatory Th17 cells are expanded and induced by dendritic cells in spondylarthritis-prone HLA-B27-transgenic rats.
|
21905004 |
2012 |
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
We aimed to assess the extent to which IL-17A-driven pathology is IL-23 dependent in experimental SpA.
|
30038617 |
2018 |
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
However, the contribution of IL-17-producing γδ T cells to SpA pathogenesis is certainly not an open-and-shut case.
|
29922283 |
2018 |
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
However, mast cells expressed significantly more interleukin-17 (IL-17) in SpA than in RA synovitis, and mast cells constituted the major IL-17-expressing cell population in the SpA synovium.
|
21968742 |
2012 |
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Finally, IL-17 and IL-23 inhibitors reduce the clinical manifestations of SpA.
|
28850053 |
2017 |
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
IL-17A blockade was performed in HLA-B27/human β<sub>2</sub> -microglobulin (hβ<sub>2</sub> m)-transgenic rats, which served as a model for SpA in both prophylactic and therapeutic settings.
|
30390386 |
2019 |
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
The recent introduction of antibodies blocking IL-17 has expanded the therapeutic options for SpA, as well as psoriasis and psoriatic arthritis.
|
30941119 |
2019 |
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Targeted Delivery of the HLA-B<sup>∗</sup>27-Binding Peptide into the Endoplasmic Reticulum Suppresses the IL-23/IL-17 Axis of Immune Cells in Spondylarthritis.
|
29463951 |
2017 |
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
RORγt inhibition selectively targets IL-17 producing iNKT and γδ-T cells enriched in Spondyloarthritis patients.
|
30602780 |
2019 |
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Murine models of interleukin (IL)-23-driven spondyloarthritis (SpA) have demonstrated entheseal accumulation of γδT-cells which were responsible for the majority of local IL-17A production.
|
31530557 |
2019 |
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis.
|
30266977 |
2018 |
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Neutralization of IL-17 ameliorates uveitis but damages photoreceptors in a murine model of spondyloarthritis.
|
22269151 |
2012 |
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
TNFi and IL-17Ai may be used in axSpA, but physicians have more experience with TNFi.
|
31095430 |
2019 |
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Nevertheless, a number of knowledge gaps exist regarding the role of IL-17A in the pathophysiology of spondyloarthritis in man, including its cellular origin, its precise role in discrete disease processes such enthesitis, bone erosion, and bone formation, and the reasons for the discrepant responses to IL-17A inhibition observed in certain other spondyloarthritis manifestations.
|
31278139 |
2019 |
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Other targeted cytokines associated with IL-17 axis in SpA will also be included.
|
29670461 |
2018 |
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Cell surface HLA-B27 FHC binding to these immune receptors or acting through other mechanisms could impact on the pathogenesis of spondyloarthritis by promoting immune cell production of IL-17.
|
23910730 |
2014 |
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Interleukin-17A has been identified as a master cytokine in the inflammatory response and pathogenesis of PsA and spondyloarthritis in general.
|
29187009 |
2018 |
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Translational data in humans have demonstrated an increase in the number of ILC3s responsive to IL-23 and producing either IL-22 or IL-17 in the gut of SpA patients.
|
31197599 |
2019 |
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Knowledge regarding the mechanisms of the IL17-IL23 pathway and its role in spondyloarthritis (SpA) has been pivotal to the development of IL-17 blockade in patients with axial SpA.
|
28149838 |
2017 |
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Despite a ballooning therapeutic tool box, treatment responses to newer biologic agents and oral small molecules in psoriatic arthritis (PsA) and spondyloarthritis (SpA) are of similar magnitude to those observed with anti-Tumor Necrosis Factor (TNF) medications (1, 2).The PsA and SpA therapeutic outcomes stand in marked contrast to those reported in psoriasis where blockade of molecules in the IL-23/IL-17 pathway often provide prolonged, deep responses and in some cases even remission (3).
|
31736273 |
2020 |
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
IL-17 and IFN-γ producing NK and γδ-T cells are preferentially expanded in synovial fluid of patients with reactive arthritis and undifferentiated spondyloarthritis.
|
28390966 |
2017 |
Spondylarthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Spondyloarthritis (SpA), a chronic inflammatory, rheumatic disease, and hidradenitis suppurativa (HS), a chronic, debilitating, inflammatory skin disease, share several clinical and pathophysiological features, such as the association with inflammatory bowel disease and elevated cytokine levels IL-17 and TNF-α.
|
29751976 |
2019 |